natgillin/translations-raw huggingface dataset:
Preferably, W and W′ are the same or different and are OH, OMe, OEt, NHCONH2, SMe. 
Spojevi u skladu s patentnim zahtjevima 1 do 3, naznačeni time što W i W' su isti ili različiti i jesu OH, OMe, OEt, NHCONH., SMe.
It is generally known that amino acid betaine salts usually have good solubility in water. 
Općenito je poznato da unutarnje soli amino kiselina, betaini, imaju uobičajeno dobru topivost u vodi.
Hard gelatin capsules may contain granules of the compound of the invention. 
Kapsule od tvrde želatine mogu sadržavati granule spoja iz ovoga izuma.
The tissue is preferably derived from the mesoderm. 
(a) tkivo je dobiveno iz mezoderma;
The aqueous agrochemical suspension composition of [1], wherein an amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 5 to 60 parts by weight, an amount of the inorganic thickener is within a range of 4 to 30 parts by weight and an amount of the dispersant is within a range of 5 to 85 parts by weight, as opposed to 100 parts by weight of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1, gdje suspenzija je kompozicija 1 količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 5 do 60 dijelova po masi, količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 4 do 30 dijelova po masi i količina dispergirajućeg sredstva je u okviru opsega od 5 do 85 dijelova po masi, za razliku od 100 dijelova po masi 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5-dihidrooksazola.
is hydrogen, C1 to C12 alkyl, phenyl unsubstituted or substituted by C1 to C12 alkyl or COR6 acyl group; R6 being hydrogen, C1 to C12 straight chain or branched alkyl, phenyl or benzoyl, respectively, unsubstituted or substituted by C1 to C12 alkyl, or any group leading to hydroxyl upon biological metabolization or chemical deprotection, the group being an ester, ether, acetale, carbonate, carbamate, phosphate, phosphonate, ketal, sulfate, or sulfonate, and salts thereof. 
je vodik, C1 do C12 alkil, fenil koji nije supstituiran ili je supstituiran s C1 do C12 alkilnom ili COR6 acilnom skupinom; je vodik, C1 do C12 nerazgranati ili razgranati alkil, fenil ili benzoil, koji odgovarajuće nije supstituiran ili je supstituiran s C1 do C12 alkilnom, ili bilo kojom skupinom koja se pretvara u hidroksilnu biološkim metaboliziranjem ili kemijskim uklanjanjem zaštite, gdje je navedeni spoj 4-hidroksitestosteron, ili njegove soli ili esteri.
For example, the compound of the present invention could therefore be useful in the treatment of a variety of PGD2-mediated disorders including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je u kristalnom obliku. Farmaceutski pripravak, naznačen time što sadrži farmaceutski djelotvornu količinu spoja u skladu s patentnim zahtjevom 1 u smjesi s farmaceutski prihvatljivom podlogom. Upotreba spoja u skladu s patentnim zahtjevom 1, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje alergijske bolesti, sistemske mastocitoze, poremećaja praćenog sistemskom aktivacijom mastocita, anafilaktičkog šoka, bronhokonstrikcije, bronhitisa, koprivnjače, ekcema, bolesti praćenih svrbežom, bolesti koja je sekundarna posljedica ponašanja praćenog svrbežom, upale, kroničnih opstruktivnih plućnih bolesti, ishemično- Teperfuzijske ozljede, cerebrovaskularnog akcidenta, kroničnog reumatoidnog artritisa, pleurizma, ili ulceroznog kolitisa.
determine power consumption of the apparatuses; and control the apparatuses in the chain. The apparatus according to claim 13, wherein the head apparatus receives energy from a power source and data signal from a data source. 
Sustav u skladu s patentnim zahtjevom 1, naznačen time što se primarnu jedinicu (SA, 5B, 5C) može upotrijebiti za prijem energije iz izvora napajanja i podatkovnog signala iz izvora podataka.
A compound of formula III and a salt formed by a compound of formula III and an organic or inorganic base. 
[image] i sol stvorena od spoja formule III i od organske ili anorganske baze. [image]
The container 13 therefore executes a stroke movement during the tensioning operation and during the atomising operation. 
Zbog toga spremnik 13 vrši udarni pomak tijekom postupka naprezanja i tijekom postupka atomizacije.
1, the liquefied gas treatment system 100 according to the present embodiment includes a fuel supply line 110 and a BOG line 140 . 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što je element za dekomprimiranje (22) ekspanzijski ventil ili ekspander.
The pharmaceutical composition according to claim 41, formulated to provide a daily dosage ranging from 50 mg to 200 mg of said lipid compound. 
Farmaceutski pripravak prema zahtjevu 29, naznačen time da je formuliran da osigurava dnevnu dozu od 50 mg do 200 mg navedenog lipidnog spoja.
posaconazole, wherein posaconazole is selected from crystalline form I or II of posaconazole or a mixture thereof; 
(i) posakonazola, pri čemu je posakonazol odabran od kristalnog oblika I ili I posakonazola ili njihove mješavine;
The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof comprises a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 32 and wherein the heavy chain variable framework region comprises at least one amino acid modification, wherein the amino acid modification comprises an amino acid substitution, from the corresponding heavy chain variable framework region of the corresponding murine antibody of SEQ ID NO: 7. 
Protutijelo ili njegov fragment sukladno patentnom zahtjevu 1, naznačeno time da, protutijelo ili njegov fragment sadrži sekvencu teškog lanca koja sadrži aminokiselinsku sekvencu SEK ID BR: 32 i pri čemu promjenjiva okvirna regija teškog lanca sadrži najmanje jednu modifikaciju amino kiseline iz odgovarajućeg promjenjive regije teškog lanca odgovarajućeg mišjeg protutijela.
The process according to any one of aspects 1 to 12, wherein before or during or after steps c) and/or d) a dispersing agent is added. 
Postupak prema bilo kojem od zahtjeva 1 do 12, gdje se prije ili za vrijeme ili nakon koraka c) i/ili d) dodaje sredstvo za disperziju.
The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein B3 is H or C1-C5 alkyl. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein B3 is H or C1-C5 alkyl. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-12, ili njena farmaceutski prihvatljiva sol, pri čemu je B3s H ili C;-Cg alkil. 14. Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol, koja ima formulu:
In one embodiment, the amino acid at heavy chain amino acid position 12 is Valine (V). 
(a) na aminokiselinskoj poziciji 12 jakog lanca, odabire aminokiselina valin (V);
Unlike known solutions, each scraping device 7 of mixing member 1 is substantially defined by a preferably, though not necessarily, plastic or metal scraper 8, which is hinged to the body of longitudinal blade 4 so as to project from and oscillate about an axis of rotation B locally substantially parallel to outer lateral edge 4b of longitudinal blade 4 and/or to longitudinal axis A of mixing member 1, and extends in a direction substantially tangent to the circular path travelled by outer lateral edge 4b as mixing member 1 rotates about longitudinal axis A, while remaining locally substantially perpendicular to axis B. 
Za razliku od poznatih rješenja, svako strugalo 7 članka za miješanje 1 je u biti definirano pogodnim, premda ne i nužnim, plastičnim ili metalnim strugačem 8, koji je obješen na tijelo uzdužne lopatice 4 tako da strši i oscilira oko osi rotacije B lokalno u biti paralelne vanjskom bočnom bridu 4b uzdužne lopatice 4 i/ili uzdužne osi A članka za miješanje 1 i pruža se u smjeru u biti tangencijalnom na kružni put kojim se kreće vanjski bočni brid 4b, kako članak za miješanje 1 rotira oko uzdužne osi A, dok u biti ostaje lokalno okomit na os B.
The method of claim 16, wherein the progeny T cells in the human comprise a memory T cell. 
T stanica za upotrebu prema patentnom zahtjevu 10, naznačena time što potomstvo T stanica u čovjeku sadrži memorijsku T stanicu.
The features and advantages of a recoil damper system according to this invention will be more evident in the following description, which is by way of example only and not restrictive, in reference to the enclosed diagrams in which: FIG. 
Karakteristike i prednosti sustava za prigušivanje trzanja koji su u skladu s ovim izumom, biti će vidljivi u opisu koji slijedi i koji je prikazan kao primjer i ne ograničava ova ovaj izum na taj prikaz, pri čemu se vrši pozivanje na priložene crteža koji prikazuju sljedeće: sika 1
The blood brain barrier shuttle of claim 5 comprising the full length IgG antibody as brain effector entity, the linker and one scFab directed to the transferrin receptor recognizing an epitope in the transferrin receptor comprised within the amino acid sequence of Seq. 
Prijenosnik za krvno-moždanu barijeru prema zahtjevu 5, naznačen time, da obuhvaća IgG protutijelo pune duljine kao entitet moždanog efektora, povezivač i jedan scFab usmjeren na receptor transferina koji prepoznaje epitop na receptoru transferina koji se nalazi unutar aminokiselinskog slijeda Seq.
The antibody drug conjugate of any one of claims 1-3, wherein the anti-DLL3 antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, CDR-grafted antibody, humanized antibody, human antibody, primatized antibody, multispecific antibody, bispecific antibody, monovalent antibody, multivalent antibody, diabody, Fab fragment, F(ab')2 fragment, Fv fragment, and ScFv fragment; or an immunoreactive fragment thereof that specifically binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO: 3 or 4. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je protutijelo anti-DLL3 odabrano iz skupine koju čine monoklonalno protutijelo, kimerno protutijelo, CDR-cijepljeno protutijelo, humanizirano protutijelo, ljudsko protutijelo, primatizirano protutijelo, multispecifično protutijelo, bispecifično protutijelo, monovalentno protutijelo, multivalentno protutijelo, diabody, Fab-fragment, F(ab'),-fragment, Fv- fragment i ScFv-fragment; ili njegov imunoreaktivni fragment koji se specifično veže na epitop unutar DSL-domene od DLI.3-proteina prema SEQ ID NO:3 ili SEQ ID NO:4.
receiving response information of the user responding to the visual signals and the one or more modulated signals for the respective frequency bands; and 
Postupak prema Zahtjevu 9, koji dalje sadrži, u slučaju da korisnik uslijed poboljšanja sluha čuje jedan ili više moduliranih signala za respektivne frekvencijske opsege:
A dosing cap according to claim 1, wherein the cap comprises an adjuster for controlling the position of the box with respect to the covering plate. 
Dozirni čep (1) u skladu s patentnim zahtjevom 1, naznačen time što čep sadrži regulator (30) za kontrolu položaja okvira (6; 16) u odnosu na pokrovnu ploču (7).
The apparatus of claim 8, wherein said supercritical trough is further filled with distillation packing therein. 
Uređaj u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži uređaj za kontrolu temperature, radi kontroliranja temperature u navedenom superkritičnom koritu.
The process according to either claim 5 or claim 6, wherein said step of coupling together said sheet materials is performed via a process of lamination (108). 
Postupak u skladu s bilo patentnim zahtjevom 5 ili patentnim zahtjevom 6, naznačen time što se navedeni korak spajanja navedenih materijala za foliju zajedno provodi postupkom laminiranja (108).
the concentration of zinc in the culture medium is in the range of 0.6 µM to 6.5 µM, optionally wherein the concentration of zinc in the culture medium is in the range of 0.6 µM to 1.1 µM; and/or 
koncentracija cinka u mediju kulture je u rasponu od 0,6 µM do 6,5 µM, proizvoljno pri čemu koncentracija cinka u mediju kulture je u rasponu od 0,6 µM do 1,1 µM; i/ili
The compound for use according to claim 7 wherein the cancer is selected from the group comprising leukemia, pancreatic, prostate, lung, breast; cervical cancer; oesophageal; gastrointestinal, including gastric, small intestine, colon and rectum, cancer; head and neck cancer; and ovarian cancer. 
Spoj prema bilo kojem od patentnih zahtjeva od 1 do 12 naznačen time da je za upotrebu u postupku profilakse ili tretmana raka kod čovjeka, poželjno da je rak odabran iz grupe koju čine leukemija, rak pankreasa, prostate, pluća, dojke i grla maternice.
the alkylsulfonyl optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl; and 
(a) alkilsulfonil je po izboru supstituiran jednim ili dva supstituenta neovisno odabranima iz skupine koja sadrži karboksi, hidroksi, halo, amino, nitro, okso, aminosulfonil, alkiloksikarbonil, alkilkarboniloksi, alkiloksi, karbociklil, heterociklil, cijano i aminokarbonil; i
if X3 in DB1 represents -X3a and X3b- and ring B is aromatic, then two vicinal substituents on said ring B are joined to form an optionally substituted carbocycle or heterocycle fused to said ring B; 
ako X3 u DB1 predstavlja -X3a i X3b-, a prsten B je aromatski, dva vicinalna supstituenta na navedenom prstenu B su povezani kako bi tvorili izborno supstituirani karbocikl ili heterocikl kondenziran s navedenim prstenom B;
In some embodiments, pharmaceutical compositions can be in the form of a powder, paste, granulates, tablets, capsules, pessaries, cream, ointment, suppository, suspension or solution. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je u obliku tableta, kapsula, krema ili granula za suspenziju.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method according to any of embodiments 1-8, wherein the method comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-5, pri čemu postupak sadrži primjenu terapeutski djelotvorne količine acetil-leucina na subjektu kojemu je to potrebno kroz razdoblje odabrano od barem 3 oko mjeseca, barem oko 6 mjeseci, barem oko 1 godine, barem oko 2 godine i barem oko 5 godina.
Hydrolysis of Peak 1 to give Isomer C 20% aqueous sodium hydroxide solution (53 ml) was added to a stirred solution of Mosher's ester peak 1 (2.37 g, 4.43 mmol) in methanol (158 ml) and the mixture stirred at reflux for 150 minutes. 
Hidroliza Peak-a 1 da bi se dobio Izomer € 20%-tna vodena otopina natrij hidroksida (53 ml) se doda u miješanu otopinu Mosher-ovog estera peak-a 1 (2.37 g, 4.43 mmol) u metanolu (158 ml) i smjesa se miješa uz refluks tijekom 150 minuta.
The process of claim 1, wherein at least 95%, or at least 99%, of an amount of the API that would have been released from uncoated core particles of a same composition and size in a USP dissolution test indicative of dissolution in the GI tract is released within 30 minutes. 
Postupak sukladno zahtjevu 1, naznačeno time, da se najmanje 95% ili najmanje 99% od količine API koja bi bio oslobođen od neobloženih čestica jezgre istog sastava i veličine u USP testu otapanja indikatora otapanja u GI trakt, se otpušta u roku od 30 minuta.
A pharmaceutical composition comprising the compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier; 
Farmaceutski sastav koji sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegovu farmaceutski prihvatljivu sol ili njegov solvat 1 farmaceutski prihvatljiv nosač.
A method of treating a colorectal cancer, a head and neck cancer, a pancreatic cancer, a breast cancer, a gastric cancer, a bladder cancer, a vulvar cancer, a leukemia, a lymphoma, a melanoma, a renal cell carcinoma, an ovarian cancer, a brain cancer, an osteosarcoma, or a lung cancer which comprises administering to a patient in need thereof a therapeutically effective amount of a compound which is 1-[5-bromo-4-methyl-2-S-(morpholin-2-ylmethoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea or a pharmaceutically acceptable salt thereof. 
5. Upotreba spoja u skladu s patentnim zahtjevom I, ili njegove farmaceutski prihvatljive soli, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kolorektalnog rak, raka glave i vrata, raka gušterače, raka dojke, raka želuca, raka mokraćnog mjehura, raka stidnice, leukemije, limfoma, melanoma, karcinoma bubrežnih stanica, raka jajnika, raka na mozgu, osteosarkoma ili raka pluća. t>&
Method of assembling interconnectable panels, in particular as claimed in any of the claims 1-43, for forming a covering, comprising the steps of: providing a first panel, 
Metoda za sklapanje međusobno spojivih ploča (1, 42, 43, 46, 53, 57) u skladu s bilo kojim od prethodnih patentnih zahtjeva 1-23, za oblikovanje pokrova, obuhvaća sljedeće korake:
Immunoglobulin (Ig) is defined as any of the structural cell antigen receptors; it is divided into five classes (IgM, IgG, IgA, IgD and IgE) on the basis of structure and biologic activity. 
Imunoglobulin (Ig) se definira kao strukturni stanični receptor za antigene, a na temelju strukture i biološke aktivnosti može se podijeliti u pet skupina (IgM, IgG, IgA, IgD 1 IgE).
g of venlafaxine hydrochloride were dissolved in 918 g of purified water. 
LP-01A 525 g venlafaksin-hidroklorida otopi se u 918 g pročišćene vode.
Forty-five minutes after dosing administration, rats were anaesthetized with sodium pentobarbital (40 mg/kg, i.p.) 
45 minuta nakon datog doziranja, štakori su anestezirani s natrijevim pentobarbitalom (40 mg/kg, 1.p.)
In particular, the second guiding passage is useful when treating a patient for incontinence. 
Naročito je drugi prolaz za vođenje koristan kada se liječi pacijent radi inkontinencije.
The compound or pharmaceutically acceptable salt thereof for use of claim 11, wherein the disease is psoriasis or sarcoidosis. 
Spoj za uporabu prema zahtjevu 21, naznačen time da je stanje psorijaza ili sarkoidoza.
A core (1) according to any one of the preceding claims, characterised in that said corrugated wall (2) has an inside diameter (φi) comprised between 20 mm and 80 mm. 
Jezgra (1) prema bilo kome od prethodno spomenutih patentnih zahtjeva, naznačena time što ima valovite bočne stijenke (2), ima unutarnji promjer (;) u rasponu od 20 do 80 mm.
Use of the compound according to claim 1 or a salt thereof, for the manufacture of a pharmaceutical composition for preventing or treating a disease associated with 17BHSD type 5. Use of the compound according to claim 1 or a salt thereof, for the manufacture of a pharmaceutical composition for preventing or treating prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma. 
Komercijalni paket, naznačen time, da sadrži farmaceutski sastav, koji obuhvaća spoj prema zahtjevu 1 ili njegovu sol; te uputstvo da je spoj prema zahtjevu 1, ili njegova sol, pogodan za upotrebu ili bi ga trebalo upotrebljavati za liječenje i/ili prevenciju raka prostate, benigne prostatske hiperplazije, akni, seboreje, hirzutizma, ćelavosti, alopecije, preuranjenog puberteta, adrenalne hipertrofije, sindroma policističnih jajnika, raka dojke, endometrioze, raka pluća ili lejomioma.
Thus the invention provides a process for preparing an influenza vaccine from influenza virus that has been grown in a culture of a mammalian cell line, comprising a step in which the vaccine and/or the culture is tested for the presence of an infectious agent that can grow in said cell line but that does not grow in embryonated hen eggs, wherein the infectious agent is selected from the group consisting of: Pneumovirinae; mammalian Reoviridae; Birnaviridae; Rubulaviruses of the Paramyxoviridae family; Coronaviridae; Rhinoviruses of the Picornaviridae family; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echoviruses; Coxsackieviruses of the Enteroviruses of the Picornaviridae family; Rotavirus; Porcine picornaviruses; Parvovirus; Circovirus; and Chlamydia bacteria. 
Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi Vero stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Pneumovirinae; Metapneumovirusi iz familije Paramyxoviridae; Rubulavirusi iz familije Paramyxoviridae; Coronaviridae; Rhinovirusi iz familije Picornaviridae; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echovirusi; Coxgackievirusi od Fnterovirusa iz familije Picornaviridae, Rotavirus, svinjski picornavirusi; Parvovirus; Circovirus; bakterija Chlamydia; Reoviridae kod sisavaca.
decoding of the data of the current partition, with the exclusion of the sign, 
- < dekodiranje (SD2, SD3) podataka navedene trenutne particije, s izuzetkom navedenog predznaka,
For the preparation of sugar containing jams, usually pectin is added since it is a naturally occurring compound in fruits, and it has the ability to form a gel in the presence of sugar and acid. 
Pri pripravi džemova koji sadržavaju šećer obično se dodaje pektin jer je to spoj koji se prirodno nalazi u plodovima i posjeduje svojstvo da u prisutnosti šećera i kiseline stvara gel.
A method for producing a beverage from an ingredient-containing capsule, the method comprising the following steps: 
Postupak za pripremanje napitka iz čahure (1) koja sadržava sastojke, pri čemu ovaj postupak sadržava sljedeće korake:
The connector apparatus of Claim 1 wherein: said spool member (16) has an elongated central body portion from which transverse opposite end portions rearwardly project. 
Uređaj za spajanje prema Zahtjevu 1: gdje navedeni element (16) u obliku kalema posjeduje izduženi centralni dio tijela s kojeg se prema nazad pružaju poprečni suprotni krajevi.
identifying in a B cell from the mouse: 
(b) identifikacije u B stanici iz miša:
Optically active compounds can also be prepared from optically active starting materials, or by stereo selective synthesis. 
Optički aktivni spojevi mogu se pripraviti 1 iz optički aktivnih polaznih supstanci ili stereoselektivnom sintezom.